Review of ticagrelor in the management of acute coronary syndromes

Bibliography

• Wright RS, Anderson JL, Adams CD, 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011;57:e215-367
   PubMedGoogle Scholar
• Kushner FG, Hand M, Smith SC Jr, 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-41
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003;91:1123-5
   PubMed Web of Science ®Google Scholar
• Muller I, Besta F, Schulz C, Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-7
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-51
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-16
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD, A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66 e9-16
   PubMed Web of Science ®Google Scholar
• Jernberg T, Payne CD, Winters KJ, Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-73
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005;31:195-204
   PubMed Web of Science ®Google Scholar
• Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006;12:1255-9
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Ingall AH, Dixon J, Bailey A, Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999;42:213-20
   PubMed Web of Science ®Google Scholar
• Ueno M, Ferreiro JL, Angiolillo DJ. Update on the clinical development of cangrelor. Expert Rev Cardiovasc Ther 2010;8:1069-77
   PubMedGoogle Scholar
• Springthorpe B, Bailey A, Barton P, From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 2007;17:6013-18
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27:259-74
   PubMed Web of Science ®Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47
   PubMed Web of Science ®Google Scholar
• Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010;66:487-96
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85
   PubMed Web of Science ®Google Scholar
• Wang K, Zhou X, Huang Y, Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost 2010;104:609-17
   PubMed Web of Science ®Google Scholar
• Ohman J, Kudira R, Albinsson S, Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun 2012;418:754-8
   PubMed Web of Science ®Google Scholar
• Baldwin SA, Beal PR, Yao SY, The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004;447:735-43
   PubMed Web of Science ®Google Scholar
• Gan L, Wittfeldt A, Emanuelson H, Adenosine may mediate ticagrelor-induced dyspnea. 61st Annual Scientific Meeting American College of Cardiology. J Am Col Cardiol 2012;59:E344
   Google Scholar
• van Giezen JJ, Sidaway J, Glaves P, Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012;17:164-72
   PubMed Web of Science ®Google Scholar
• Rose JB, Naydenova Z, Bang A, Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection. Am J Physiol Heart Circ Physiol 2010;298:H771-7
   PubMed Web of Science ®Google Scholar
• Serebruany VL. Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor. Cardiology 2010;117:231-3
   PubMed Web of Science ®Google Scholar
• Patil SB, Jackman LE, Francis SE, Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima. Arterioscler Thromb Vasc Biol 2010;30:2385-91
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010;70:65-77
   PubMed Web of Science ®Google Scholar
• Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010;38:1514-21
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-6
   PubMed Web of Science ®Google Scholar
• Husted SE, Storey RF, Bliden K, Pharmacokinetics and pharmacodynamics of ticagrelor in patients with Stable Coronary Artery disease: results from the ONSET-OFFSET and RESPOND Studies. Clin Pharmacokinet 2012;51:397-409
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol 2011; Epub ahead of print
   Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment. J Clin Pharmacol 2011;51:978-87
   PubMed Web of Science ®Google Scholar
• AstraZeneca. BRILINTA (Ticagrelor) Approved Product Information. 2011
   Google Scholar
• Cannon CP, Husted S, Harrington RA, Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-51
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010;121:1188-99
   PubMed Web of Science ®Google Scholar
• James S, Akerblom A, Cannon CP, Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605
   PubMed Web of Science ®Google Scholar
• Cannon CP, Harrington RA, James S, Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-93
   PubMed Web of Science ®Google Scholar
• James S, Budaj A, Aylward P, Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010;122:1056-67
   PubMed Web of Science ®Google Scholar
• Held C, Asenblad N, Bassand JP, Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672-84
   PubMed Web of Science ®Google Scholar
• James S, Angiolillo DJ, Cornel JH, Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010;31:3006-16
   PubMed Web of Science ®Google Scholar
• Stiles S. Use low-dose aspirin with ticagrelor, PLATO analysis suggests. Acute Coronary Syndromes. 2011. Available from: http://www.theheart.org/article/1244925.do [Cited 28 June 2012]
   Google Scholar
• Mahaffey KW, Wojdyla DM, Carroll K, Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011;124:544-54
   PubMed Web of Science ®Google Scholar
• Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost 2011;105:763-5
   PubMed Web of Science ®Google Scholar
• Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011;105:752-9
   PubMed Web of Science ®Google Scholar
• Serebruany VL. Aspirin dose and ticagrelor benefit in PLATO: fact or fiction? Cardiology 2010;117:280-3
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, James SK, Harrington RA. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on serebruany. "Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost 2011;105:760-2
   PubMedGoogle Scholar
• Peters RJ, Mehta SR, Fox KA, Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-7
   PubMed Web of Science ®Google Scholar
• Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol 2011;72:619-33
   PubMed Web of Science ®Google Scholar
• Becker RC, Bassand JP, Budaj A, Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32:2933-44
   PubMed Web of Science ®Google Scholar
• Serebruany VL. The TRITON versus PLATO trials: differences beyond platelet inhibition. Thromb Haemost 2010;103:259-61
   PubMed Web of Science ®Google Scholar
• Kirkby NS, Leadbeater PD, Chan MV, Antiplatelet effects of aspirin vary with level of P2Y receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost 2011;9:2103-5
   PubMed Web of Science ®Google Scholar
• Scirica BM, Cannon CP, Emanuelsson H, The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol 2011;57:1908-16
   PubMed Web of Science ®Google Scholar
• Storey RF, Bliden KP, Patil SB, Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;56:185-93
   PubMed Web of Science ®Google Scholar
• Burki NK, Dale WJ, Lee LY. Intravenous adenosine and dyspnea in humans. J Appl Physiol 2005;98:180-5
   PubMed Web of Science ®Google Scholar
• Hong JL, Ho CY, Kwong K, Lee LY. Activation of pulmonary C fibres by adenosine in anaesthetized rats: role of adenosine A1 receptors. J Physiol 1998;508(Pt 1):109-18
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European Medicines Agency. 2012. Available from: http://www.ema.europa.eu/ema/ [Cited 06 May 2012]
   Google Scholar
• Wijns W, Kolh P, Danchin N, Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-55
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA. 2012. Available from: http://www.fda.gov/default.htm [Cited 06 May 2012]
   Google Scholar
• Levine GN, Bates ER, Blankenship JC, 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44-122
   PubMed Web of Science ®Google Scholar
• Therapeutic Goods Administration. Therapeutic Goods Administration. 2012. Available from: http://www.tga.gov.au/ [Cited 06 May 2012]
   Google Scholar
• Chew DP, Aroney CN, Aylward PE, 2011 Addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes (ACS) 2006. Heart Lung Circ 2011;20:487-502
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Prevention of Cardiovascular Events (e.g., Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS). 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01225562 [Cited 28 June 2012]
   Google Scholar